Biomarkers of M1‐TAMs in tumor tissues were tested by iNOS, and M2‐TAMs were tested by CD163 or CD206.[28, 29] In contrast to non‐smoking NSCLC patients, there was lower expression of iNOS and enhanced expression of CD163 for smoking patients (Figure 1E,F). This evidence concerns the gene CD163 and neoplasm.